Discovery of Autoantibody Biomarkers for Cancer and Autoimmune Disease Event Date: June 20, 2007 12:00 Noon Eastern Daylight Time; 9:00 a.m. Pacific Daylight Time Best viewed on Internet Explorer 6 or better.   Real Player   Real Media Audio (16k)   Real Media Video (56k/150k) For best results when using Real Media, first upgrade to RealPlayer v11.   Windows Media Player   Windows Media Audio (16k)   Windows Media Video (56k/150k)     Autoantibodies have been documented to be valuable biomarkers in a range of cancers, in addition to autoimmune diseases. A number of discovery platforms are available for the identification of disease-specific autoantibodies. Protein microarrays provide a rapid and sensitive platform for the screening of autoantibodies in easily accessible biological fluids including sera, plasma, and urine. Join our panel of experts to: Learn about the promise of autoantibodies as biomarkers for cancer and autoimmune disease. Obtain insight into how to advance your biomarker discovery research using proteomics approaches. Hear about the successful application of protein arrays to biomarker discovery in ovarian cancer.   Speakers: Eng M. Tan, M.D., Professor Emeritus, Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA Eng M. Tan is currently Professor Emeritus in the Department of Molecular & Experimental Medicine at The Scripps Research Institute. He obtained his M.D. from Johns Hopkins University School of Medicine and, besides a five-year period as a professor in the Department of Medicine at University of Colorado Health Sciences Center, Dr. Tan has been at the Scripps Institute since his first assistant professorship there in 1965. Dr. Tan sits on the editorial board of a number of prestigious journals and has been recognized by the broader scientific community as a top researcher in his field through numerous honors and awards. Currently, the focus of Dr. Tan’s research is the molecular and cell biology of autoantibodies and autoimmunity. His work seeks to identify autoantibodies and their requisite antigens to enable the development of better diagnosis and future treatments for autoimmune diseases and cancer. Michael Snyder, Ph.D., Professor, Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT Michael Snyder is the Lewis B. Cullman Professor of Molecular and Cellular Biology and Professor of Molecular Biophysics and Biochemistry at Yale University; he is also the Director of the Yale Center of Genomics and Proteomics. Dr. Snyder received his Ph.D. training in the laboratory of Dr. Norman Davidson at the California Institute of Technology and carried out postdoctoral training in Dr. Ronald Davis’s laboratory at Stanford University. He is a leader in the field of functional genomics and proteomics. His laboratory currently carries out a variety of projects in the areas of genomics and proteomics both in yeast and humans. These include the large-scale analysis of proteins using protein microarrays and the global mapping of the binding sites of chromosomal proteins. His laboratory built the first proteome chip and the first high resolution tiling array for the entire human genome. Dr. Snyder has published over 200 manuscripts and is editor of a number of journals; he sits on many international advisory boards and was a cofounder of Protometrix, Inc., a protein microarray company that was purchased by Invitrogen in 2004. Paul Predki, Ph.D., Vice President for Research and Development, Proteomics, Invitrogen Corporation, Carlsbad, CA Paul F. Predki serves as Vice President for Proteomics Research & Development at Invitrogen. Dr. Predki joined Invitrogen as part of the acquisition of Protometrix in 2004, a functional protein microarray company he helped start in 2001 as a spin-out from Yale University. Prior to that he served as Associate Director at the Department of Energy Joint Genome Institute (JGI), where he was responsible for the development and implementation of the institute's high throughput production sequencing and genomics programs. Prior to joining the JGI, Dr. Predki spent four years at the genomics biotechnology company, CuraGen Corporation. Dr. Predki has over 10 years of experience in industrial-scale biology, plus postdoctoral experience at Yale University, where he investigated protein engineering and protein biochemistry. He obtained his Ph.D. in Biochemistry from the University of Toronto. Dr. Predki has published in a variety of high-profile journals, including Science, Nature, and Cell, and most recently served as editor of the book Functional Protein Microarrays in Drug Discovery.   Moderator: Sean Sanders, Ph.D., Commercial Editor, Science/AAAS Sean Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. under Sir Dillwyn Williams at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor in 2004 before recently taking the position of Commercial Editor at Science/AAAS.   ___________________________________________________________________________________________________   Test Your System   Help   Download Real Player   Download Windows Media Player